Unidad de ETV HGUGM

The struggle is real. So much uncertainty for both clinicians and patients!
We need further research on this topic to provide better, accurate #APS diagnosis and improve patients' QoL.

Dragons’s Den of the highly fruitful www.invent-vte.com netwerk. Collaboration leads to practice-changing trials!!

#ISTH2025

Whenever you see a young male with EN and DVT, always remember to ask about oral&genital ulcers!

#VTE #thrombosis #Behçet #IMSky

This vasculitis may show multiple symptoms.
The International Criteria may be helpful in the diagnosis:

Young male + erythema nodosum (EN) + VTE...

Think of Behçet disease!

What should you absolutely think of if you see a young male with acute DVT of this leg?

#Medicine #VTE
@luciaordieres.bsky.social

Most women taking combined contraception who develop VTE state that they have never been informed of the thrombotic risk.
Do you tell your patients about the risk of blood clots?

A recent consensus tries to define the patient with acute PE that would benefit most from Hospital at Home management:
authors.elsevier.com/a/1kwL63FTR6...

#VTESky #VTE #HospitalAtHome #HemeSky

Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis Antithrombotic therapy can prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is, however, associated with an increased risk…

This goes in line with current guidelines, but we now have further evidence to support these claims.

Find the entire paper here, free of charge:
www.sciencedirect.com/science/arti...

A recent metaanalysis including 22 articles states that:

⌚️ Transient risk factor: 3-6 months of treatment superior to extended therapy.
🛌 Unprovoked VTE or chronic provoking factor: extended therapy is superior to limited.

When starting anticoagulation for VTE, there are two main points:
🔍 Diagnosis. Here, risk-benefit assessment for anticoagulation must be performed.
🗓️ 3-6 months. Here, one must consider reduced doses vs perhaps withdrawing anticoagulation completely.

Right Ventricular Perforation and Cardiac Tamponade Post-FlowTriever® System Treatment in High-Risk Pulmonary Embolism: A Rare Complication Catheter-directed thrombectomy (CDT) using the FlowTriever® system offers promising results and could represent a paradigm shift in reducing morbidity and mortality of patients with intermediate-high ...

An extremely rare complication of mechanical thrombectomy:

Right Ventricular Perforation and Cardiac Tamponade Post-FlowTriever® System Treatment in High-Risk Pulmonary Embolism: A Rare Complication

Now available at
www.cureus.com/articles/311...

#PE #thrombectomy #HemeSky #cureus #VTE

@luciaordieres.bsky.social @mmonrealriete.bsky.social
#VTE #thrombosis #VTESky #IMSky #HemeSky

This past two days, we have participated in the #5ForoETV, a national meeting on #VTE.

We have presented our studies on early discharge of DVT from the ER, ethnicity in VTE and artificial intelligence.

Always wonderful to meet people who love VTE!

online.fliphtml5.com/qimqu/kvcd/#...

Do you use, or plan to, apixaban 2.5 mg in cancer patients with VTE?
👀

#VTE #VTESky #HemeSky #IMSky #apixaban @luciaordieres.bsky.social

Results:
🫁 Non inferiority for recurrence or mortality.
🩸Less bleeding events with apixaban 2.5 mg.

This is a question many of us have asked ourselves when facing cancer patients in our clinical practice, and now we finally have an answer.

Recently published in @nejm.org, API-CAT:
👯 1766 cancer patients.
🎂 69 years old.
👨‍🦰43.4% men.
🦵 Included, in average, 8 months after VTE.
🗓️ Median follow-up 11.8 months.
💊 Apixaban 2.5 mg vs 5 mg twice daily.

You might remember the EVE trial (2023):
💊 apixaban 2.5 mg vs 5 mg twice daily in cancer patients with VTE after 6-12 months of treatment.

🩸Primary outcome: bleeding.
🗓️ Follow-up: 12 months.
👯360 patients included in analysis.

Shockingly, apixaban 2.5 mg did not reduce bleeding compared to 5 mg.

API-CAT is finally here!
t.co/7g6YSpeWmZ

This study really changes clinical practice, let's see why:
🧵

We hope this evidence helps in your daily practice!

@luciaordieres.bsky.social

#anticoagulation #thrombosis #hematology #HemeSky #ThromboSky #VTESky #Medicine

❓TUS may pose a management challenge due to the lack of solid evidence.

💊We compared 161 patients treated with DOACs vs VKAs.
⛑️Overall, no differences in major bleeding or recurrences.
🧪DOACs: Pharmacokinetic advantages.

🍺Need to individualize in some populations (liver disease...).

Clinical outcomes of direct oral anticoagulants in patients with thrombosis in unusual sites: Insights from a tertiary care center

Excited to share with you our experience with DOACs in thrombosis in unusual sites (TUS)!
Available @ThrombosisResearch

www.sciencedirect.com/science/arti...

Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies Venous thromboembolism remains a major cause of morbidity and mortality among ambulatory cancer patients, necessitating effective risk assessment and prevention strategies. Despite the availability of...

What a great resource if you look after cancer patients 🤗

www.rpthjournal.org/article/S247... @rpth.bsky.social

Our experience soon @ Thrombosis Research!

@luciaordieres.bsky.social

YouTube video by GT Tromboembólica SEMI Protocolo Filtro Vena Cava Inferior, Dr. Francisco Galeano

For those of you who understand Spanish, Dr. Galeano tells us about inferior vena cava filters:
youtu.be/qAMIJondzQI

Let’s do this

Linktr.ee/theawkwardyeti

Continuation of oral anticoagulation during TAVI led to higher bleeding rates without reducing major complications compared to interruption.

by van Ginkel DJ, Bor WL (...) Schotborgh CE et 11 al. in N Engl J Med #MedSky

📖 read the article: https://www.nejm.org/doi/10.1056/NEJMoa2407794

Now, the patient had a personal history of two miscarriages (< week 20) and pericarditis 5 years prior.
Does that change your judgment?

Genuinely curious what you think!

#VTE #HemeSky #Thrombosis #IMSky #MedSky #ClinicalCase #VTESky

This morning at the ward:
Female, 40 years old.
PE one year prior, non-provoked.
DVT six months prior (under vitK inhibitors). Treatment remained the same.
MI two months prior, changed to DOAC.
Currently admitted due to PE (incidental finding).

What would you do in this case?

1/2

Red Light Therapy May Reduce Deadly Blood Clots - Neuroscience News Exposure to long-wavelength red light significantly reduced blood clot formation in both mice and human studies.

"Can red light therapy help prevent blood clot?"
This animal study suggest that it might be possible!
#VTE #HemeSky #Thrombosis

neurosciencenews.com/red-light-th...